Economic evaluations of adult pneumococcal vaccination strategies

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 1, Issue 1, 2001, Pages 47-58

  Beutels, Philippe ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Cost utility analysis; Economic evaluation; Pneumococcal vacination; Vaccine

Indexed keywords

COTRIMOXAZOLE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EUROPE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INFECTION RISK; LIFE EXPECTANCY; NORTH AMERICA; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOCIETY; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0035557303     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.1.1.47     Document Type: Review

References (49)

1. Pneumococcal Vaccine
2. The cost effectiveness of pneumococcal vaccination strategies
3. Economic evaluations of pneumococcal vaccination. A critical analysis
4. Methods for the economic evaluation of health care programmes
5. Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended
6. Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: The results in Belgium
7. Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 western European countries
8. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium
9. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly
10. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
11. Pneumococcal immunization program: Cost-utility analysis for Québec
12. Cost-effectiveness and cost-utility of a pneumococcal immunization program in Québec (CETS)
13. Cost-effectiveness of vaccination against pneumococcal pneumonia
14. A cost-benefit analysis of immunization for pneumococcal pneumonia
15. Cost-effectiveness of vaccination against pneumococcal pneumonia: An update
16. Pneumococcal vaccine: Efficacy and associated cost savings
17. Influenza and pneumoccal vaccination of HIV-infected patients: A policy analysis
18. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease
19. A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients
20. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps
21. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines
22. Evaluation socio-énomique d'un vaccin contre l'infection pneumococcique
23. Kostenbatenanalyse van vaccinatie tegen pneumokokkenpneumonie
24. Cost-benefit analysis of pneumococcal vaccination
25. Coste-efectividad de la vacunación neumocócica en Cataluña
26. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population
27. Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands
28. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands
29. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials
30. Clinical effectiveness of pneumococcal vaccine. Meta-analysis
31. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials
32. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
33. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: A prospective study
34. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
35. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine
36. Recommendations of the Panel on Cost-effectiveness in Health and Medicine
37. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
38. Predicting cost-benefits before programs are started: Looking at conjugate vaccine for invasive pneumococcal infections
39. Theoretical foundations of cost-effectiveness analysis
40. Economic foundations of cost-effectiveness analysis
41. Accounting for future costs in medical cost-effectiveness analysis
42. Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000)
43. Economic evaluation of vaccination programmes: Specific methodological issues and results in relation to viral hepatitis
44. Five-hundred life-saving interventions and their cost-effectiveness
45. Influenza and pneumococcal vaccination of the elderly: Newer vaccines and prospects for clinical benefits at the margin
46. Pneumococcal vaccine in the prevention of community-acquired pneumonia: A skeptical view of cost-effectiveness
47. Economic Evaluation of Vaccination Programmes in Humans: A methodological exploration with applications to hepatitis B, varicella, measles, pertussis, hepatitis A and pneumococcal vaccination
48. Emerging infectious diseases
49. Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?